Lipocine (LPCN) Receivables - Other (2016 - 2025)
Lipocine (LPCN) has disclosed Receivables - Other for 11 consecutive years, with $115272.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other rose 26.01% year-over-year to $115272.0, compared with a TTM value of $115272.0 through Sep 2025, up 26.01%, and an annual FY2024 reading of $120447.0, up 130.5% over the prior year.
- Receivables - Other was $115272.0 for Q3 2025 at Lipocine, down from $121732.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $579428.0 in Q3 2022 and bottomed at $24230.0 in Q2 2023.
- Average Receivables - Other over 5 years is $164447.4, with a median of $120094.0 recorded in 2022.
- The sharpest move saw Receivables - Other surged 63136.06% in 2021, then tumbled 92.91% in 2023.
- Year by year, Receivables - Other stood at $247253.0 in 2021, then plummeted by 67.47% to $80427.0 in 2022, then crashed by 35.03% to $52254.0 in 2023, then skyrocketed by 130.5% to $120447.0 in 2024, then decreased by 4.3% to $115272.0 in 2025.
- Business Quant data shows Receivables - Other for LPCN at $115272.0 in Q3 2025, $121732.0 in Q2 2025, and $179027.0 in Q1 2025.